Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award
May 21 2024 - 8:00AM
Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic
medicines company focused on improving the lives of patients with
neurodegenerative diseases, today announced Carrie Gordon, a
sophomore at Drexel University, as the third recipient of its Tachi
Yamada Scholarship award.
The scholarship honors the legacy of Dr. Tachi Yamada,
co-founder and former Chairman of the Passage Bio Board of
Directors and is open to students enrolled in life sciences
programs at four-year colleges and universities in Pennsylvania who
seek a career in the life sciences industry.
Carrie is pursuing a Bachelor of Science degree in Biological
Science with a minor in Neuroscience. She has excelled in her
academic studies as she pursues a career in medicine and has
developed a particular interest in neurology, conducting
preclinical research on the neural morphology of genes related to
autism spectrum disorder. Carrie was selected to the Students
Tackling Advanced Research, or STAR, Scholars program and the
Aspire Scholars program and hopes to combine her passions for
volunteerism and medicine to provide healthcare to underserved
communities.
In addition to her academic and research interests, Carrie is a
member of Drexel’s chamber strings and serves on the board of the
university’s Club for Students with Visible and Invisible
Disabilities.
“The Passage Bio team is excited to award the third annual Tachi
Yamada Scholarship to Carrie Gordon. Carrie’s first-hand
experiences with the healthcare system have forged her passion for
pursuing a career in medicine and giving back to those in need. She
exemplifies the qualities this scholarship program seeks to honor
and is a worthy recipient of this award,” said William Chou, M.D.,
president and chief executive officer of Passage Bio. “We are
honored to support Carrie in her pursuits and look forward to her
continued achievements."
Through the scholarship, Carrie will receive financial
assistance towards college-related expenses and will be matched
with a Passage Bio mentor for professional growth opportunities
over the two-year scholarship period.
Passage Bio first announced its plans to launch the annual Tachi
Yamada Scholarship Program in October 2021 to continue the legacy
of Tadataka (Tachi) Yamada, M.D., a visionary biopharma industry
leader who passed away in August 2021. Dr. Yamada had a life-long
devotion to mentoring and building the next generation of
scientists.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines
company on a mission to improve the lives of patients with
neurodegenerative diseases. Our primary focus is the development
and advancement of cutting-edge, one-time therapies designed to
target the underlying pathology of these conditions. Passage Bio’s
lead product candidate, PBFT02, seeks to treat neurodegenerative
conditions, including frontotemporal dementia, by elevating
progranulin levels to restore lysosomal function and slow disease
progression.
To learn more about Passage Bio and our steadfast commitment to
protecting patients and families against loss in neurodegenerative
conditions, please
visit: www.passagebio.com.
For further information, please contact:
Investors:Stuart HendersonPassage
Bio267.866.0114shenderson@passagebio.com
Media:Mike BeyerSam Brown Inc. Healthcare
Communications312.961.2502MikeBeyer@sambrown.com
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Jul 2024 to Aug 2024
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Aug 2023 to Aug 2024